TCGA-22-5491-01A-01R-1635-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.610
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.490
- MTORC1_SIGNALING+0.420
- DNA_REPAIR+0.380
- G2M_CHECKPOINT+0.360
- FATTY_ACID_METABOLISM+0.320
- PEROXISOME+0.320
- P53_PATHWAY+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- ANGIOGENESIS-0.490
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- IL6_JAK_STAT3_SIGNALING-0.370
- COAGULATION-0.350
- UV_RESPONSE_DN-0.350
- ALLOGRAFT_REJECTION-0.340
- INFLAMMATORY_RESPONSE-0.320
- TGF_BETA_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.935 |
| 2 | TCGA-18-3412-01A-01R-0980-07 | — | cohortSQ2 | 0.927 |
| 3 | TCGA-XF-A8HB-01A-11R-A36F-07 | — | — | 0.916 |
| 4 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.906 |
| 5 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.904 |
| 6 | ERR2278847 | — | — | 0.903 |
| 7 | ERR2278860 | — | — | 0.902 |
| 8 | TCGA-CV-7180-01A-11R-2016-07 | — | — | 0.901 |
| 9 | af606e0b-b19b-4c8d-9cf5-6a195978466e | — | — | 0.897 |
| 10 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.610 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |